TP53 mutations are enriched in HER2-positive biliary tract cancer and drive poor outcomes
TP53 mutations act as an independent poor prognostic factor in biliary tract cancer
Figure 1: A) rwOS analysis for patients with BTC, treated with 1L GC+D and stratified by TP53 mutation status (anchored on 1L therapy start. B) Oncoplot comparing mutational frequency between HER2- and HER2+ patients.
Lens Library
